October 1, 2015
Novartis Announces NEJM Publication of Secukinumab Phase III
Novartis announced on Wednesday that results from the pivotal Phase III FUTURE 1 study for Secukinumab in psoriatic arthritis (PsA)…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Phase III FUTURE 1